Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Core Insights - Can-Fite BioPharma Ltd. is hosting a webinar on February 25, 2025, to discuss its development pipeline and milestones [1][2] - The company has multiple out-licensing deals and potential regulatory and sales milestone payments exceeding $130 million, with $20 million already received [2] - Can-Fite's advanced-stage assets target unmet medical needs in markets valued over $70 billion, positioning the company for potential commercialization [2] Company Overview - Can-Fite BioPharma Ltd. is focused on developing proprietary small molecule drugs for oncological and inflammatory diseases [1][4] - The lead drug candidate, Piclidenoson, has reported positive Phase III trial results for psoriasis and is set to begin a pivotal Phase III trial [4] - Namodenoson, another key drug, is in various stages of clinical trials for conditions such as Metabolic Dysfunction-associated Steatohepatitis (MASH) and hepatocellular carcinoma (HCC) [4] - Namodenoson has received Orphan Drug Designation in the U.S. and Europe and Fast Track Designation for HCC treatment [4] - CF602, a third drug candidate, has shown efficacy in treating erectile dysfunction [4] Financial Highlights - Can-Fite has secured $20 million in upfront and milestone payments, indicating strong potential for its therapies [2] - The company is strategically positioned to capitalize on a market with a combined value exceeding $70 billion [2]